Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

This study is for people with a specific type of pancreatic cancer that cannot be removed by surgery. It combines **radiotherapy** (using high-energy rays to kill cancer cells) with two medicines: *envafolimab* and *capecitabine*. Envafolimab is given as a weekly shot under the skin, while capecitabine is taken as pills twice a day for two weeks, followed by a one-week break. The study checks if this combination is safe and effective.

• The study lasts until the disease progresses or side effects become too much.
• Participants must visit the hospital regularly for treatments and monitoring.
• Risks include side effects from treatments, and eligibility requirements are strict.

To join, you must be between 18-90 years old, have certain lab test results, and not have certain other health issues or allergies. You should not be pregnant or breastfeeding. This study offers a chance to try a new treatment, but it may have risks and requires commitment. Always discuss with your doctor before participating. 😊